Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) is now available.
Qyuns Therapeutics Co., Ltd. announced the completion of subject enrollment for its Phase III clinical trial of QX005N, an innovative treatment for prurigo nodularis (PN). This trial, the largest of its kind globally, marks a significant milestone for the company and the Chinese biopharmaceutical industry, addressing the unmet clinical needs of approximately 2 million PN patients in China. The trial aims to evaluate the efficacy of QX005N in relieving itching, with previous Phase II trials showing promising results. The successful development of QX005N could enhance Qyuns Therapeutics’ market positioning and provide a breakthrough in treating PN.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a Chinese company operating in the biopharmaceutical industry, focusing on the development of innovative therapies for inflammatory and allergic diseases. Its primary product, QX005N, is a humanized monoclonal antibody targeting the IL-4 receptor alpha subunit, with applications in treating conditions such as prurigo nodularis, atopic dermatitis, and asthma.
YTD Price Performance: 36.59%
Average Trading Volume: 66,788
Technical Sentiment Consensus Rating: Buy
Learn more about 2509 stock on TipRanks’ Stock Analysis page.